Swiss Go Trial Group Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2020
NCT04111978
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Swiss Go Trial Group

Active Ingredients

Drugs in Phase 3 Trials (1)

letrozole (femara) (1 trial)

Drugs in Phase 2 Trials (1)

apx005m (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 3)

Fallopian Tube Neoplasms (Phase 3)

Neoplasms (Phase 3)

Ovarian Neoplasms (Phase 3)

Peritoneal Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2